World J Mens Health.  2012 Dec;30(3):183-188.

Relationship between Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia and Metabolic Syndrome in Korean Men

• Park YW
• Min SK
• Lee JH

Abstract

PURPOSE
To investigate any associations between lower urinary tract symptoms (LUTS)/benign prostate hyperplasia (BPH) and metabolic syndrome (MetS).
MATERIALS AND METHODS
In all, 1,224 male police officers in their 50s who had participated in health examinations were included. LUTS/BPH was assessed by serum prostate-specific antigen, International Prostate Symptom Score (IPSS), transrectal ultrasonography, maximum urinary flow rate (Q max), and postvoid residual urine volume (PVR). In addition, testosterone was also examined. The MetS was defined using NCEP-ATP III guidelines. We used the multiple linear regression test and logistic regression analyses to examine the relationships.
RESULTS
MetS was diagnosed in 29.0% of participants. There was no significant difference in the percentage of cases of BPH (IPSS >7, Q max <15 ml/sec, and prostate gland volume > or = 20 ml) (14.2% in the non-MetS group vs. 17.2 in the MetS group; p value=0.178). The total IPSS score and the Q max were not significantly different. The prostate volume and PVR were significantly greater in the subjects with MetS. After adjusting for age and testosterone, the presence of MetS was not associated with BPH (multivariate odds ratio, 1.122; 95% confidence interval, 0.593~2.120). Additionally, MetS was not related to IPSS (Beta, -0.189; p value=0.819), prostate volume (Beta, 0.815; p value=0.285), Q max (Beta, -0.827; p value=0.393), or PVR (Beta, 0.506; p value=0.837).
CONCLUSIONS
According to our results, the MetS was not clearly correlated with LUTS/BPH in Korean men in their 50s.

Keyword

Benign prostatic hyperplasia; Metabolic syndrome; Lower urinary tract symptoms

MeSH Terms

Humans
Hyperplasia
Linear Models
Logistic Models
Lower Urinary Tract Symptoms
Male
Odds Ratio
Police
Prostate
Prostate-Specific Antigen
Prostatic Hyperplasia
Testosterone
Urinary Tract
Prostate-Specific Antigen
Testosterone

Reference

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984. 132:474–479.

2. De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012. 61:560–570.

3. Gao Y, Wang M, Zhang H, Tan A, Yang X, Qin X, et al. Are metabolic syndrome and its components associated with lower urinary tract symptoms? Results from a Chinese male population survey. Urology. 2012. 79:194–201.

4. Hong GS, Shim BS, Chung WS, Yoon H. Correlation between metabolic syndrome and lower urinary tract symptoms of males and females in the aspect of gender-specific medicine: a single institutional study. Korean J Urol. 2010. 51:631–635.

5. Ohgaki K, Hikima N, Horiuchi K, Kondo Y. Association between metabolic syndrome and male lower urinary tract symptoms in Japanese subjects using three sets of criteria for metabolic syndrome and International Prostate Symptom Score. Urology. 2011. 77:1432–1438.

6. Park HK, Lee HW, Lee KS, Byun SS, Jeong SJ, Hong SK, et al. Korean Longitudinal Study on Health and Aging. Relationship between lower urinary tract symptoms and metabolic syndrome in a community-based elderly population. Urology. 2008. 72:556–560.

7. Shigehara K, Namiki M. Late-onset hypogonadism syndrome and lower urinary tract symptoms. Korean J Urol. 2011. 52:657–663.

8. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. American Heart Association. National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005. 112:2735–2752.

9. Siroky MB, Olsson CA, Krane RJ. The flow rate nomogram: I. Development. J Urol. 1979. 122:665–668.

10. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet. 1991. 338:469–471.

11. Chute CG, Panser LA, Girman CJ, Oesterling JE, Guess HA, Jacobsen SJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol. 1993. 150:85–89.

12. Parsons JK, Kashefi C. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. Eur Urol. 2008. 53:1228–1235.

13. Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Goodman P, Penson DF, et al. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2008. 167:925–934.